New Molecular Testing Guidelines Pending for Colorectal Cancer

Meir Rinde
Published: Wednesday, Jul 08, 2015
Carmen J. Allegra, MD

Carmen J. Allegra, MD

All patients with colorectal cancer being considered for treatment with the epidermal growth receptor (EGFR) inhibitors cetuximab and panitumumab should undergo extended RAS mutational testing to predict their response to the drugs, according to a new molecular marker testing guideline being developed by the American Society of Clinical Oncology (ASCO) and three leading pathology organizations.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication